Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX7 + Camrelizumab + Apatinib for Stage III HCC
NCT05412589Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen Memorial Hospital. Started Jun 2022; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05412589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05412589.